Grant Supports Phase 3 Trial of FCX-007 for RDEB

Grant Supports Phase 3 Trial of FCX-007 for RDEB

310654

Grant Supports Phase 3 Trial of FCX-007 for RDEB

The U.S. Food and Drug Administration (FDA) has awarded Castle Creek Biosciences a research grant to support its Phase 3 clinical trial of FCX-007 (dabocemagene autoficel), an investigational gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The grant of $1.82 million, which comes from the agency’s Orphan Products Grants Program, is for four years. The focus of this program is on the development of therapeutics for patients with a rare disease like…

You must be logged in to read/download the full post.